Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

European Biopharmaceutical Companies Launch Anticancer Drug Project

By BiotechDaily International staff writers
Posted on 12 Nov 2013
Two European biopharmaceutical companies are joining forces in an intensive effort to develop a new series of anticancer drugs.

ZoBio (Leiden, The Netherlands) will be applying its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target protein.

TINS is a powerful approach that has been validated on a wide range of targets including viral proteins, proteases, kinases, protein-protein interaction targets, molecular chaperones, and membrane proteins. TINS uses a single sample of the target and a reference protein that have been immobilized on Sepharose-based resin. Fragments to be assayed for binding are injected as mixtures of between three and nine compounds. Binding is detected by a reduction in the height of the NMR signals of a compound that specifically binds to the target. Comparison of the NMR spectra of the fragments in the presence of the target and reference proteins directly reveals the identity of the binding ligand.

ZoBio offers its proprietary TINS technology for ligand screening studies on its own, highly validated fragment library or the customer’s. A typical TINS discovery and characterization/validation project is completed in one to two months.

ZoBio's partner in the new project is Actelion Ltd. (Allschwil, Switzerland), a company that has demonstrated global leadership in the field of pulmonary arterial hypertension (PAH) therapy. Actelion is known for a strong and effective worldwide specialty commercial organization, a highly productive discovery capability, and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.

Dr. Gregg Siegal, CSO of ZoBio said, “We are proud that Actelion, a company with such success in bringing innovative drugs to the market, has selected ZoBio as a partner. We feel that this collaboration has a great chance to succeed where others have failed.”

Related Links:

Actelion Ltd.



view channel
Image: Micrograph showing immunofluorescence of skin differentiation markers for basal keratinocytes (Photo courtesy of Dr. Russ Carstens, University of Pennsylvania).

Alternate Splicing Proteins Critically Linked to Skin and Organ Development

Two proteins that regulate alternative splicing in epithelial cells have been linked to the proper development of the skin and protective layers that surround other organs in the body. Two steps are... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.